Say goodbye to repeat surgeries? This new heart implant valve grows with your child

Clearance from the US Food and Drug Administration (FDA) now allows Edwards’ Autus Size-Adjustable Valve to reach pediatric patients. This artificial pulmonary implant represents the first device engineered to expand after surgery, accommodating a child’s physical development without requiring repeated operations.

Addressing congenital valve defects

Data published in the National Library of Medicine indicates that roughly 400,000 children born annually in the United States present with some form of congenital heart disease. Approximately 30 percent of these cases involve valve abnormalities, where tissue flaps fail to function as one-way doors for proper blood flow.

The Centers for Disease Control and Prevention notes that stenosis and atresia affect about 4,200 babies in the US each year. Stenosis describes a narrowed valve, while atresia refers to the failure of the valve to form normally. These conditions specifically impact the pulmonary valve located on the right side of the heart.

Eliminating repeat surgeries

Traditional artificial pulmonary valves necessitate a series of replacement surgeries as patients grow, requiring progressively larger implants. The Autus valve can be implanted at a diameter as small as 13 millimeters in toddlers and preschool-aged children. For older patients, surgeons may expand the device prior to implantation.

The critical innovation lies in the ability to enlarge the valve inside the body post-surgery. Using a balloon catheter—a thin tube with an inflatable tip—clinicians can adjust the device to keep pace with growth. The Autus reaches a maximum diameter of 22 millimeters, matching the size of standard adult artificial valves.

Polymeric material advantages

Beyond its adjustable nature, the Autus is the first heart valve to utilize polymeric material for its flaps. Conventional implants rely on synthetic flaps derived from animal tissues, which tend to harden and break down more rapidly in children, often triggering additional surgical interventions.

The FDA states that follow-up data collected one year after implantation suggests the Autus holds up better over time compared to other existing models. Reducing the frequency of surgeries lessens associated risks for children managing congenital heart diseases.